Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.
Daniela Kroshinsky, MD, MPH
Advertisement
Daniela Kroshinsky, MD, MPH, works in the Department of Dermatology at the Duke University School of Medicine.
Articles by Daniela Kroshinsky, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Tavapadon for Parkinson Disease Approved by FDA
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5